Obesity and the liver: nonalcoholic fatty liver disease (Q38229961)

31 August 2017

title

Obesity and the liver: nonalcoholic fatty liver disease (English)

1 reference

metabolic dysfunction–associated steatotic liver disease

31 August 2017

0 references

0 references

1 reference

Sean W P Koppe

1

1 reference

31 August 2017

publication date

25 June 2014

1 reference

31 August 2017

published in

Translational Research

1 reference

31 August 2017

volume

164

1 reference

31 August 2017

issue

4

1 reference

31 August 2017

page(s)

312-322

1 reference

Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988-1994

31 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

Increasing prevalence of nonalcoholic fatty liver disease among United States adolescents, 1988-1994 to 2007-2010.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

Nonalcoholic fatty liver disease: pathologic patterns and biopsy evaluation in clinical research

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

Long-term follow-up of patients with NAFLD and elevated liver enzymes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

Steatosis: co-factor in other liver diseases.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

Declining liver utilization for transplantation in the United States and the impact of donation after cardiac death.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

The natural history of non-alcoholic fatty liver disease in children: a follow-up study for up to 20 years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

A feed-forward loop amplifies nutritional regulation of PNPLA3

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

PNPLA3 I148M polymorphism and progressive liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

Association between the PNPLA3 (rs738409 C>G) variant and hepatocellular carcinoma: Evidence from a meta-analysis of individual participant data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

Chronic overexpression of PNPLA3I148M in mouse liver causes hepatic steatosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

Patatin-like phospholipase domain-containing protein 3 rs738409-G in recipients of liver transplants is a risk factor for graft steatosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

Visceral obesity modulates the impact of apolipoprotein C3 gene variants on liver fat content

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

Apolipoprotein CIII overexpressing mice are predisposed to diet-induced hepatic steatosis and hepatic insulin resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

The SOD2 C47T polymorphism influences NAFLD fibrosis severity: Evidence from case-control and intra-familial allele association studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

Genomic aspects of NAFLD pathogenesis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

Splanchnic lipolysis in human obesity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

Hepatic triglyceride synthesis and nonalcoholic fatty liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

Diacylglycerol activation of protein kinase Cε and hepatic insulin resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

A lipidomic analysis of nonalcoholic fatty liver disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

Cellular mechanism of insulin resistance in nonalcoholic fatty liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

Intrahepatic diacylglycerol content is associated with hepatic insulin resistance in obese subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

Hepatic insulin resistance in mice with hepatic overexpression of diacylglycerol acyltransferase 2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

High fat diet induces ceramide and sphingomyelin formation in rat’s liver nuclei

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

Bioinformatics strategies for lipidomics analysis: characterization of obesity related hepatic steatosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

Inhibition of ceramide synthesis ameliorates glucocorticoid-, saturated-fat-, and obesity-induced insulin resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

Central role of ceramide biosynthesis in body weight regulation, energy metabolism, and the metabolic syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

Role of ceramides in nonalcoholic fatty liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

Lipid-induced insulin resistance mediated by the proinflammatory receptor TLR4 requires saturated fatty acid-induced ceramide biosynthesis in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

Hepatic cytochrome P450 2E1 activity in nondiabetic patients with nonalcoholic steatohepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

Mitochondrial dysfunction in liver disease and organ transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

NASH: a mitochondrial disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

CYP2E1 and oxidant stress in alcoholic and non-alcoholic fatty liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

Increased expression of cytochrome P450 2E1 in nonalcoholic fatty liver disease: mechanisms and pathophysiological role

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

The plasma lipidomic signature of nonalcoholic steatohepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

Systemic levels of lipid peroxidation and its metabolic and dietary correlates in patients with nonalcoholic steatohepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

Mass spectrometric profiling of oxidized lipid products in human nonalcoholic fatty liver disease and nonalcoholic steatohepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

The unfolded protein response: a stress signaling pathway critical for health and disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

Disruption of endoplasmic reticulum structure and integrity in lipotoxic cell death

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

Decrease in membrane phospholipid unsaturation induces unfolded protein response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

Endoplasmic reticulum stress is reduced in tissues of obese subjects after weight loss

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

Activation and dysregulation of the unfolded protein response in nonalcoholic fatty liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

Endoplasmic reticulum stress markers are associated with obesity in nondiabetic subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

Beyond insulin resistance in NASH: TNF-alpha or adiponectin?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

Serum total adiponectin in nonalcoholic fatty liver disease: a systematic review and meta-analysis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

Hepatic fat loss in advanced nonalcoholic steatohepatitis: are alterations in serum adiponectin the cause?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

Toll-like receptors and adaptor molecules in liver disease: update

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

Inflammatory role of Toll-like receptors in human and murine adipose tissue

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

The role of lipopolysaccharide/toll-like receptor 4 signaling in chronic liver diseases.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

Fatty acid-induced induction of Toll-like receptor-4/nuclear factor-kappaB pathway in adipocytes links nutritional signalling with innate immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

TLR4 links innate immunity and fatty acid-induced insulin resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

Linking long-term dietary patterns with gut microbial enterotypes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

The Gordian Knot of dysbiosis, obesity and NAFLD.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

Germ-free C57BL/6J mice are resistant to high-fat-diet-induced insulin resistance and have altered cholesterol metabolism.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

Validation of terminal peptide of procollagen III for the detection and assessment of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

Advanced fibrosis in nonalcoholic fatty liver disease: noninvasive assessment with MR elastography

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

Liver stiffness measurements in patients with different stages of nonalcoholic fatty liver disease: diagnostic performance and clinicopathological correlation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

Effects of weight loss induced by bariatric surgery on hepatic adipocytokine expression.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

Weight loss amelioration of non-alcoholic steatohepatitis linked to shifts in hepatic ceramide expression and serum ceramide levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

Gastric bypass surgery reduces plasma ceramide subspecies and improves insulin sensitivity in severely obese patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

Improved hepatic lipid composition following short-term exercise in nonalcoholic fatty liver disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

Short-term exercise reduces markers of hepatocyte apoptosis in nonalcoholic fatty liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

Physical activity recommendations, exercise intensity, and histological severity of nonalcoholic fatty liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

2011 Compendium of Physical Activities: a second update of codes and MET values

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

Dietary trans-fatty acid induced NASH is normalized following loss of trans-fatty acids from hepatic lipid pools

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

Trans fat feeding results in higher serum alanine aminotransferase and increased insulin resistance compared with a standard murine high-fat diet

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

US moves to ban trans fats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

Long term nutritional intake and the risk for non-alcoholic fatty liver disease (NAFLD): a population based study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

The role of fructose in the pathogenesis of NAFLD and the metabolic syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

Fructose induced lipogenesis: from sugar to fat to insulin resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

Association of coffee drinking with total and cause-specific mortality

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

Effects of habitual coffee consumption on cardiometabolic disease, cardiovascular health, and all-cause mortality

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

Coffee consumption and risk of type 2 diabetes: a systematic review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

Association of coffee and caffeine consumption with fatty liver disease, nonalcoholic steatohepatitis, and degree of hepatic fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

Impact of coffee on liver diseases: a systematic review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

Coffee reduces risk for hepatocellular carcinoma: an updated meta-analysis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

How does coffee prevent liver fibrosis? Biological plausibility for recent epidemiological observations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

Adenosine 2A receptor antagonist prevented and reversed liver fibrosis in a mouse model of ethanol-exacerbated liver fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

Vitamin E and nonalcoholic fatty liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

PPARγ signaling and metabolism: the good, the bad and the future

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-gamma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

Pioglitazone treatment increases whole body fat but not total body water in patients with non-alcoholic steatohepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

Effects of pentoxifylline on nonalcoholic fatty liver disease: a meta-analysis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

Pentoxifylline decreases oxidized lipid products in nonalcoholic steatohepatitis: new evidence on the potential therapeutic mechanism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

Immunomodulatory properties of pentoxifylline are mediated via adenosine-dependent pathways

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

Protective effects of pentoxifylline in pulmonary inflammation are adenosine receptor A2A dependent

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

Adenosine receptors and fibrosis: a translational review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

Non-alcoholic Fatty liver disease: the bile Acid-activated farnesoid x receptor as an emerging treatment target

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

The farnesoid X receptor induces very low density lipoprotein receptor gene expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

Farnesoid X receptor is essential for normal glucose homeostasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

FXR is a molecular target for the effects of vertical sleeve gastrectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

Serum bile acids are higher in humans with prior gastric bypass: potential contribution to improved glucose and lipid metabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

Vertical sleeve gastrectomy reduces hepatic steatosis while increasing serum bile acids in a weight-loss-independent manner

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

Allosteric inhibition of lysyl oxidase–like-2 impedes the development of a pathologic microenvironment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

Statins in nonalcoholic fatty liver disease and steatohepatitis: updated review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.008

10.1016/J.TRSL.2014.06.008

7 January 2021

Identifiers

DOI

1 reference

31 August 2017

1 reference